An Oncolytic Vaccinia Virus Expressing Anti-CD47 Nanobody Exerts Enhanced Antitumor Activity by Mediating Innate and Adaptive Immune Cell Infiltration and Activation in the Lymphoma Tumor Microenvironment

In an implanted subcutaneously lymphoma mouse model, oncolytic vaccine virus (OVV)-mCD47nb demonstrated superior therapeutic efficacy and significantly prolonged survival of tumor-bearing mice when compared to its parental OVV.